Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

March 29, 2024

FDA approves Gilead’s Vemlidy sNDA for paediatric HBV patients

The US Food and Drug Administration (FDA) has granted approval for Gilead Sciences’ supplemental new drug application (sNDA) for Vemlidy (tenofovir alafenamide) 25 mg tablets to treat chronic hepatitis B virus (HBV) in paediatric patients.

FDA approves Gilead’s Vemlidy sNDA for paediatric HBV patients